Lilly’s COVID-19 antibody drugs are a top seller this quarter, but investors aren’t that excited
April 27, 2021 at 14:34 PM EDT
Eli Lilly's COVID-19 monoclonal antibody treatments brought in $810.1 million in global sales in the first three months of the year, but investors remain largely lukewarm about therapies that they expect to have a short lifespan.